Aurobindo Pharma receives USFDA nod for Vecuronium Bromide Injection

24 Dec 2018 Evaluate

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Vecuronium Bromide Injection, 10mg and 20mg. Aurobindo’s Vecuronium Bromide Injection is a generic equivalent of Organon’s Norcuron Injection. The product will be launched in Q4FY19.

Vecuronium Bromide Injection is used as part of general anesthesia to provide skeletal muscle relaxation during surgery or mechanical ventilation. It is also used to facilitate endotracheal intubation. The approved product has an estimated market size of $11 million for the twelve months ending September 2018 according to IQVIA.

This is the 58th ANDA to be approved out of Unit IV formulation facility in Hyderabad, India used for manufacturing general injectable & ophthalmic products. The company now has a total of 397 ANDA approvals (369 Final approvals including 20 from Aurolife Pharma LLC and 28 tentative approvals) from USFDA.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1172.75 -8.45 (-0.72%)
01-Jan-2026 10:15 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1712.55
Dr. Reddys Lab 1254.70
Cipla 1503.65
Zydus Lifesciences 908.85
Lupin 2084.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×